12/9
12:20 pm
vtvt
vTv Therapeutics Inc. (NASDAQ: VTVT) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $35.00 price target on the stock.
Medium
Report
vTv Therapeutics Inc. (NASDAQ: VTVT) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $35.00 price target on the stock.
12/9
07:33 am
vtvt
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
Low
Report
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER
12/2
04:19 pm
vtvt
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference [Yahoo! Finance]
Medium
Report
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference [Yahoo! Finance]
12/2
04:05 pm
vtvt
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
Medium
Report
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
11/21
04:14 am
vtvt
Diabetes Pipeline Landscape Research Report 2024: Comprehensive Insights About 200+ Companies and 200+ Pipeline Drugs [Yahoo! Finance]
Medium
Report
Diabetes Pipeline Landscape Research Report 2024: Comprehensive Insights About 200+ Companies and 200+ Pipeline Drugs [Yahoo! Finance]
11/17
07:34 am
vtvt
vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71% [Yahoo! Finance]
Medium
Report
vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71% [Yahoo! Finance]
11/12
04:05 pm
vtvt
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update
Medium
Report
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update
11/8
02:56 am
vtvt
Marsh breaks ground on expansion [Yahoo! Finance]
Low
Report
Marsh breaks ground on expansion [Yahoo! Finance]